Wockhardt Limited
WOCKPHARMA
Rang in Aktien
#4503
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Aktienkurs
$21.02
Marktkapitalisierung
$3.42B
Veränderung (1 Tag)
-2.48%
Veränderung (1 Jahr)
37.78%
Land
IN
Handel Wockhardt Limited (WOCKPHARMA)
Kategorie
Healthcare
EPS für Wockhardt Limited (WOCKPHARMA)
EPS zum June 2026 TTM: $0.28
Laut den aktuellen Finanzberichten und dem Aktienkurs von Wockhardt Limited beträgt das aktuelle EPS des Unternehmens (TTM) $0.28. Am Ende des Jahres 2024 betrug das EPS $-0.39 ein Rückgang im Vergleich zu dem EPS von 2023, das $-0.47 betrug.
EPS-Verlauf von Wockhardt Limited von 2004 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $0.28 | -794.25% |
| 2025 | $-0.04 | -90.88% |
| 2024 | $-0.39 | -18.45% |
| 2023 | $-0.47 | 77.08% |
| 2022 | $-0.27 | -21.59% |
| 2021 | $-0.34 | 73.20% |
| 2020 | $-0.20 | -47.92% |
| 2019 | $-0.38 | -55.39% |
| 2018 | $-0.84 | 209.37% |
| 2017 | $-0.27 | -179.67% |
| 2016 | $0.34 | -41.89% |
| 2015 | $0.59 | -53.86% |
| 2014 | $1.28 | -51.83% |
| 2013 | $2.65 | 366.49% |
| 2012 | $0.57 | 232.75% |
| 2011 | $0.17 | -109.11% |
| 2010 | $-1.88 | 678.46% |
| 2008 | $-0.24 | -129.20% |
| 2007 | $0.83 | 80.04% |
| 2006 | $0.46 | -4.80% |
| 2005 | $0.48 | 16.08% |
| 2004 | $0.41 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $2.41 | 767.84% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | 87.25% |
US
|
